This company has been marked as potentially delisted and may not be actively trading. Oaktree Acquisition (OAC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock OAC vs. BLCO, RDNT, SLNO, OPCH, ALKS, HNGE, TMDX, VKTX, TGTX, and ACADShould you be buying Oaktree Acquisition stock or one of its competitors? The main competitors of Oaktree Acquisition include Bausch + Lomb (BLCO), RadNet (RDNT), Soleno Therapeutics (SLNO), Option Care Health (OPCH), Alkermes (ALKS), Hinge Health (HNGE), TransMedics Group (TMDX), Viking Therapeutics (VKTX), TG Therapeutics (TGTX), and ACADIA Pharmaceuticals (ACAD). These companies are all part of the "medical" sector. Oaktree Acquisition vs. Its Competitors Bausch + Lomb RadNet Soleno Therapeutics Option Care Health Alkermes Hinge Health TransMedics Group Viking Therapeutics TG Therapeutics ACADIA Pharmaceuticals Oaktree Acquisition (NYSE:OAC) and Bausch + Lomb (NYSE:BLCO) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings. Do insiders and institutionals have more ownership in OAC or BLCO? 47.6% of Oaktree Acquisition shares are held by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are held by institutional investors. 0.8% of Bausch + Lomb shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more risk & volatility, OAC or BLCO? Oaktree Acquisition has a beta of 0.17, meaning that its share price is 83% less volatile than the S&P 500. Comparatively, Bausch + Lomb has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Which has higher valuation & earnings, OAC or BLCO? Oaktree Acquisition has higher earnings, but lower revenue than Bausch + Lomb. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOaktree AcquisitionN/AN/A$1.15MN/AN/ABausch + Lomb$4.79B1.10-$317M-$0.78-19.13 Does the media refer more to OAC or BLCO? In the previous week, Bausch + Lomb had 9 more articles in the media than Oaktree Acquisition. MarketBeat recorded 9 mentions for Bausch + Lomb and 0 mentions for Oaktree Acquisition. Bausch + Lomb's average media sentiment score of 0.48 beat Oaktree Acquisition's score of 0.00 indicating that Bausch + Lomb is being referred to more favorably in the news media. Company Overall Sentiment Oaktree Acquisition Neutral Bausch + Lomb Neutral Is OAC or BLCO more profitable? Oaktree Acquisition has a net margin of 0.00% compared to Bausch + Lomb's net margin of -5.58%. Bausch + Lomb's return on equity of 2.33% beat Oaktree Acquisition's return on equity.Company Net Margins Return on Equity Return on Assets Oaktree AcquisitionN/A N/A N/A Bausch + Lomb -5.58%2.33%1.12% Do analysts recommend OAC or BLCO? Bausch + Lomb has a consensus price target of $15.56, suggesting a potential upside of 4.22%. Given Bausch + Lomb's stronger consensus rating and higher probable upside, analysts plainly believe Bausch + Lomb is more favorable than Oaktree Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oaktree Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Bausch + Lomb 1 Sell rating(s) 7 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.18 SummaryBausch + Lomb beats Oaktree Acquisition on 10 of the 13 factors compared between the two stocks. Get Oaktree Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for OAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OAC vs. The Competition Export to ExcelMetricOaktree AcquisitionOffices & Clinics Of Medical Doctors IndustryMedical SectorNYSE ExchangeMarket Cap$1.11B$33.61M$5.83B$21.17BDividend YieldN/AN/A3.84%3.59%P/E RatioN/AN/A31.1629.17Price / SalesN/A0.60474.8654.97Price / Cash377.4554.0337.1523.84Price / Book219.800.399.115.45Net Income$1.15M-$7.06M$3.26B$992.10M Oaktree Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OACOaktree AcquisitionN/A$43.96+1.3%N/A+161.8%$1.11BN/A0.00N/AHigh Trading VolumeBLCOBausch + Lomb2.2155 of 5 stars$13.75+0.9%$15.56+13.2%-10.1%$4.82B$4.79B-17.6213,500RDNTRadNet3.3155 of 5 stars$63.60+2.6%$69.60+9.4%+8.7%$4.65B$1.83B-317.9811,021News CoverageInsider TradeSLNOSoleno Therapeutics4.5607 of 5 stars$83.36-2.8%$113.30+35.9%+34.6%$4.56B$32.66M-20.1430News CoverageAnalyst ForecastAnalyst RevisionOPCHOption Care Health4.5637 of 5 stars$28.54+2.5%$35.75+25.3%-10.3%$4.52B$5.00B22.838,088News CoveragePositive NewsInsider TradeGap UpALKSAlkermes4.8083 of 5 stars$27.43+3.4%$41.08+49.8%+2.8%$4.38B$1.56B13.191,800Trending NewsAnalyst RevisionHNGEHinge HealthN/A$55.86+0.3%$55.71-0.3%N/A$4.35B$480.79M0.001,514TMDXTransMedics Group2.8744 of 5 stars$131.13+3.0%$123.00-6.2%-31.3%$4.34B$441.54M67.94210Positive NewsVKTXViking Therapeutics4.0243 of 5 stars$39.86+4.4%$86.92+118.1%-60.4%$4.29BN/A-26.0520Trending NewsAnalyst ForecastOptions VolumeTGTXTG Therapeutics4.3598 of 5 stars$27.12+2.8%$46.25+70.5%+14.8%$4.19B$454.07M73.30290Positive NewsACADACADIA Pharmaceuticals3.9511 of 5 stars$25.45+2.5%$28.88+13.5%+55.6%$4.19B$1.02B19.14510Insider TradeHigh Trading Volume Related Companies and Tools Related Companies Bausch + Lomb Competitors RadNet Competitors Soleno Therapeutics Competitors Option Care Health Competitors Alkermes Competitors Hinge Health Competitors TransMedics Group Competitors Viking Therapeutics Competitors TG Therapeutics Competitors ACADIA Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:OAC) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oaktree Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oaktree Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access